Featured Research

from universities, journals, and other organizations

Blood Clotting Protein May Inhibit Spinal Cord Regeneration

Date:
July 6, 2007
Source:
University of California - San Diego
Summary:
Fibrinogen, a blood-clotting protein found in circulating blood, has been found to inhibit the growth of central nervous system neuronal cells, a process that is necessary for the regeneration of the spinal cord after traumatic injury. The findings may explain why the human body is unable to repair itself after most spinal cord injuries.

Fibrinogen, a blood-clotting protein found in circulating blood, has been found to inhibit the growth of central nervous system neuronal cells, a process that is necessary for the regeneration of the spinal cord after traumatic injury. The findings by researchers at the University of California, San Diego (UCSD) School of Medicine, may explain why the human body is unable to repair itself after most spinal cord injuries.

The study, led by Katerina Akassoglou, Ph.D., assistant professor in UCSD's Department of Pharmacology, is the first evidence that when blood leaks into the nervous system, the blood protein contributes to the neurons' inability to repair themselves. The findings show the molecular link between vascular and neuronal damage during injury to the central nervous system.

The research team studied three types of spinal cord injuries in mice and rats which resulted in cellular and vascular damage, and leakage of fibrinogen from the blood vessels. Once injured, neurons cannot be repaired because of various inhibitors that are present in the brain and the spinal cord after damage, which results in a patient's paralysis. The researchers were surprised at the massive deposits of fibrinogen found at the sites of injury. That discovery led them to investigate the protein's effect on neuronal cells' ability to regenerate.

"Our study shows that fibrinogen directly affects neurons by inhibiting their ability for repair," said Akassoglou. Fibrinogen -- contained in the blood which leaks at the site of injury -- begins the process of inhibiting axonal growth by binding to the beta 3 integrin receptor. This binding, in turn, induces the activation of another receptor on the neuronal cells, called the epidermal growth factor receptor. When the second receptor is activated, it inhibits the axonal growth. Other inhibitors have been identified that use the same epidermal growth factor receptor, but this is the first blood-derived inhibitor that has been found.

The discovery may open the door to a possible strategy to improving recovery after spinal cord injury by discovering a way to block activation of neuronal receptors by fibrinogen. Identifying the specific inhibitors that impede the repair process could provide ways to regenerate and connect the damaged nerves and initiate recovery from paralysis after spinal cord injury.

"Inhibiting the damaging effects of fibrinogen on neurons may potentially facilitate repair in the nervous system after injury" said Akassoglou. A similar mechanism could be at work in other neurological diseases that result in paralysis, such as multiple sclerosis or hemorrhagic stroke, where blood vessels break and bleed into the brain. She added that such a therapeutic approach wouldn't interfere with fibrinogen's essential role in coagulation, because its blood-clotting mechanism depends on binding with a different receptor.

This research was published in the online issue of the Proceedings of the National Academy of Sciences on July 2.

Additional contributors to the paper include first author Christian Schachtrup, Jerry Lu and Ben D. Sachs of UCSD's Department of Pharmacology, and Paul Lu, Jae K. Lee and Binhai Zheng of UCSD's Department of Neurosciences. The research was funded in part by grants from the German Research Foundation, National Multiple Sclerosis Society, National Institute of Neurologic Diseases and Stroke (NIH/NINDS) and the Christopher Reeve and Sam Schmidt Paralysis Foundation.


Story Source:

The above story is based on materials provided by University of California - San Diego. Note: Materials may be edited for content and length.


Cite This Page:

University of California - San Diego. "Blood Clotting Protein May Inhibit Spinal Cord Regeneration." ScienceDaily. ScienceDaily, 6 July 2007. <www.sciencedaily.com/releases/2007/07/070703171831.htm>.
University of California - San Diego. (2007, July 6). Blood Clotting Protein May Inhibit Spinal Cord Regeneration. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2007/07/070703171831.htm
University of California - San Diego. "Blood Clotting Protein May Inhibit Spinal Cord Regeneration." ScienceDaily. www.sciencedaily.com/releases/2007/07/070703171831.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins